---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-058199"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:26:33.403259+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting

## Summary
- Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.
- All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).
- Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.
- Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.
- Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved.

## SEC filing metadata
- accession: 0001104659-25-058199
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/0001104659-25-058199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/tm2517622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-058199
- JSON: https://secwatch.observer/filing/0001104659-25-058199.json
- Plain text: https://secwatch.observer/filing/0001104659-25-058199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.